Single-agent immune checkpoint inhibition (ICI) has shown encouraging efficacy in thyroid cancer patients. This group reports the clinical outcomes of a phase II study of dual anti-PD-L1/CTLA-4 inhibition with durvalumab and tremelimumab in patients with advanced thyroid cancer.
- Jaume Capdevila
- Jorge Hernando
- Teresa Alonso-Gordoa